Cargando…
What Is the Role of HSCT in Philadelphia-Chromosome–Positive and Philadelphia-Chromosome–Like ALL in the Tyrosine Kinase Inhibitor Era?
Previously, the outcome of paediatric Philadelphia-chromosome–positive (Ph(+)) ALL treated with conventional chemotherapy alone was poor, necessitating the use of haematopoietic stem cell transplantation (HSCT) for the best outcomes. The recent addition of tyrosine kinase inhibitors (TKIs) alongside...
Autores principales: | Vettenranta, Kim, Dobsinska, Veronika, Kertész, Gabriella, Svec, Peter, Buechner, Jochen, Schultz, Kirk R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848997/ https://www.ncbi.nlm.nih.gov/pubmed/35186828 http://dx.doi.org/10.3389/fped.2021.807002 |
Ejemplares similares
-
PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022) -
The Philadelphia chromosome in leukemogenesis
por: Kang, Zhi-Jie, et al.
Publicado: (2016) -
Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute lymphoblastic leukemia
por: Akahoshi, Yu, et al.
Publicado: (2019) -
Philadelphia chromosome duplication as a ring-shaped chromosome
por: Borjas-Gutierrez, Cesar, et al.
Publicado: (2016) -
Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells
por: Okabe, Seiichi, et al.
Publicado: (2018)